Researchers have devoted considerable effort to identifying and characterizing RAD52 inhibitors for synthetic lethality strategies in BRCA1/2-depleted cancers and in cells with drug-induced BRCA1/2 depletion. This evidence concerns the gene BRCA1 and cancer.